PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising cancer therapeutics especially for tumors with deficient homologous recombination (HR) repair. However, as HR-deficient tumors represent only a small fraction of endometrial cancers, the therapeutic utility of PARP inhibitors i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncogene
Main Authors: Bian, X, Gao, J, Luo, F, Rui, C, Zheng, T, Wang, D, Wang, Y, Roberts, T M, Liu, P, Zhao, J J, Cheng, H
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5799770/
https://ncbi.nlm.nih.gov/pubmed/28945226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2017.326
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados